mftreatment.com
Link authority for mftreatment.com (registrable domain: mftreatment.com) from the Common Crawl web graph: PageRank and harmonic centrality history since 2017, current scores, and the site's top backlink sources.
Web-graph authority (0-100)
Domain scores measure mftreatment.com as a whole: every subdomain's links rolled up into one node of Common Crawl's domain-level web graph. Host scores measure the exact hostname mftreatment.com. WWW scores cover the www variant of that hostname, which the graph tracks as its own entry since January 2026 (before that, www and bare host were merged). A big gap between domain and host usually means the domain's authority lives on other subdomains. PageRank is link-endorsement authority: how much weight the sites linking here carry themselves. Harmonic centrality measures reach: how close this site sits to the rest of the web when following links, which favors broadly connected sites over ones boosted by a few heavy linkers. All are normalized 0 to 100 within each crawl snapshot; a dash means that series does not exist for this site.
Homepage
What mftreatment.com presents on its own homepage: the page title, description, and the social share markup it publishes. Pulled from http://mftreatment.com.
| Title | Polycythemia Vera, Myelofibrosis, Acute & Chronic Graft-Versus-Host Disease | Jakafi®/Jakafi XR™ (ruxolitinib) |
|---|---|
| Description | Learn about Jakafi®/Jakafi XR™ (ruxolitinib) – Used to treat adults with polycythemia vera who have taken hydroxyurea and it did not work well enough or they could not tolerate it, and adults with certain types of myelofibrosis. Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough. Jakafi is also used to treat adults and children 12 years of age and older with chronic GVHD who have taken one or two types of treatments and they did not work well enough. |
Social accounts and contact points
Where this site maintains a presence and every reachable route its homepage exposes: social accounts, contact pages, addresses, and content feeds.
| Contact pages | http://mftreatment.com/contact-us |
|---|
Structured data (JSON-LD)
The schema.org markup this homepage publishes: the machine-readable identity search engines and AI systems read. Types found: MedicalWebPage, ItemList, MedicalIndication.
JSON-LD block (1,066 bytes)
{
"@context": "https://schema.org/",
"@type": "MedicalWebPage",
"audience": "https://schema.org/Patient",
"specialty": "https://schema.org/Oncologic",
"about": "Polycythemia Vera, Myelofibrosis, Acute & Chronic Graft-Versus-Host Disease | Jakafi®/Jakafi XR™ (ruxolitinib)",
"url":"https://www.jakafi.com/",
"description": "Learn about Jakafi®/Jakafi XR™ (ruxolitinib) – Used to treat adults with polycythemia vera who have taken hydroxyurea and it did not work well enough or they could not tolerate it, and adults with certain types of myelofibrosis. Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough. Jakafi is also used to treat adults and children 12 years of age and older with chronic GVHD who have taken one or two types of treatments and they did not work well enough.",
"image": {
"@type": "ImageObject",
"url":"https://www.jakafi.com/sites/g/files/hssmmz9556/themes/site/images/og-logo.png"
}
}
JSON-LD block (694 bytes)
{
"@context":"https://schema.org",
"@type":"ItemList",
"itemListElement":[
{
"@type": "SiteNavigationElement",
"position": 1,
"name": "Polycythemia Vera",
"url":"https://www.jakafi.com/polycythemia-vera/"
},
{
"@type": "SiteNavigationElement",
"position": 2,
"name": "Myelofibrosis",
"url":"https://www.jakafi.com/myelofibrosis/"
},
{
"@type": "SiteNavigationElement",
"position": 3,
"name": "Acute Graft-Versus-Host Disease",
"url":"https://www.jakafi.com/acute-graft-versus-host-disease/"
},
{
"@type": "SiteNavigationElement",
"position": 4,
"name": "Chronic Graft-Versus-Host Disease",
"url":"https://www.jakafi.com/chronic-graft-versus-host-disease/"
}
]
}
JSON-LD block (2,328 bytes)
{
"@context": "https://schema.org",
"@graph":
[
{
"@context": "https://schema.org",
"type":
"MedicalCondition",
"name":
"Myelofibrosis",
"sameAs":
"https://en.wikipedia.org/wiki/Primary_myelofibrosis",
"code": "D75.81",
"possibleTreatment":
{
"@type": "MedicalTherapy",
"drug":
{
"@type": "Drug",
"name": "Jakafi® (ruxolitinib)",
"proprietaryName": "JAKAFI",
"nonProprietaryName": "Ruxolitinib tablets",
"mainEntityOfPage": "[site:url]myelofibrosis/",
"dosageForm": "tablet",
"administrationRoute": "oral",
"drugUnit": "mg",
"activeIngredient": "ruxolitinib",
"availableStrength": "5mg,10mg,15mg,20mg,25mg",
"mechanismOfAction": "Oral JAK inhibition",
"prescriptionStatus": "Available by prescription",
"doseSchedule": {
"@type": "DoseSchedule",
"doseUnit": "mg",
"doseValue": "5",
"frequency": "Twice daily",
"targetPopulation": "Adult patients",
"description": "For adults with intermediate- or high-risk MF, the recommended starting doses are based on platelet counts"
},
"manufacturer":
{
"name": "Incyte Corporation",
"description": "Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.",
"url": "https://incyte.com/",
"Brand":
{
"@type": "Brand",
"name": "JAKAFI",
"url": "[site:url]myelofibrosis/"
}
}
}
}
},
{
"@type": "MedicalIndication",
"name":"JAKAFI (ruxolitinib) INDICATION AND USAGE",
"description":
[
"Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults."
]
}
]
}
JSON-LD block (2,094 bytes)
{
"@context":"https://schema.org",
"@graph":
[
{
"@context": "https://schema.org",
"type": "MedicalCondition",
"name": "Polycythemia vera (PV)",
"sameAs": "https://en.wikipedia.org/wiki/Polycythemia_vera",
"code": "D45",
"possibleTreatment":
{
"@type": "MedicalTherapy",
"drug":
{
"@type": "Drug",
"name": "Jakafi® (ruxolitinib)",
"proprietaryName": "JAKAFI",
"nonProprietaryName": "Ruxolitinib tablets",
"mainEntityOfPage": "[site:url]polycythemia-vera/",
"dosageForm": "tablet",
"administrationRoute": "oral",
"drugUnit": "mg",
"activeIngredient": "ruxolitinib",
"availableStrength": "5mg,10mg,15mg,20mg,25mg",
"prescriptionStatus": "Available by prescription",
"doseSchedule": {
"@type": "DoseSchedule",
"doseUnit": "mg",
"doseValue": "10",
"frequency": "Twice daily",
"targetPopulation": "Adult patients"
},
"manufacturer":
{
"name": "Incyte Corporation",
"description": "Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.",
"url": "https://incyte.com/",
"Brand":
{
"@type": "Brand",
"name": "JAKAFI",
"url": "[site:url]polycythemia-vera/"
}
}
}
}
},
{
"@type": "MedicalIndication",
"name":"JAKAFI (ruxolitinib) INDICATION AND USAGE",
"description":
[
"Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea."
]
}
]
}
JSON-LD block (2,259 bytes)
{
"@context":"https://schema.org",
"@graph":
[
{
"@context": "https://schema.org",
"type": "MedicalCondition",
"name": "Chronic graft-versus-host disease (cGVHD)",
"sameAs": "https://en.wikipedia.org/wiki/Graft-versus-host_disease#Chronic",
"code": "D89.811",
"possibleTreatment":
{
"@type": "MedicalTherapy",
"drug":
{
"@type": "Drug",
"name": "Jakafi® (ruxolitinib)",
"proprietaryName": "JAKAFI",
"nonProprietaryName": "Ruxolitinib tablets",
"mainEntityOfPage": "[site:url]chronic-graft-versus-host-disease/",
"dosageForm": "tablet",
"administrationRoute": "oral",
"drugUnit": "mg",
"activeIngredient": "ruxolitinib",
"availableStrength": "5mg,10mg,15mg,20mg,25mg",
"mechanismOfAction": "Oral JAK inhibition",
"prescriptionStatus": "Available by prescription",
"doseSchedule": {
"@type": "DoseSchedule",
"doseUnit": "mg",
"doseValue": "10",
"frequency": "Twice daily",
"targetPopulation": "Patients ages 12 and older"
},
"manufacturer":
{
"name": "Incyte Corporation",
"description": "Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.",
"url": "https://incyte.com/",
"Brand":
{
"@type": "Brand",
"name": "JAKAFI",
"url": "[site:url]chronic-graft-versus-host-disease/"
}
}
}
}
},
{
"@type": "MedicalIndication",
"name":"JAKAFI (ruxolitinib) INDICATION AND USAGE",
"description":
[
"Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older."
]
}
]
}
Authority over time
Every Common Crawl web-graph release since 2017, roughly quarterly. The domain series goes back to 2017; Common Crawl only began publishing the host-level graph in 2020, so host lines start there. Click a legend entry to show or hide that line. Flat lines are normal for established sites; watch for sustained rises or drops, which track real gains or losses in who links here.
A note on www: through the end of 2025 the source web graph merged www and non-www hostnames into the bare name, so one host line covers both. Starting in January 2026 the graph splits them into separate entries, which is why www can carry its own scores going forward.
Backlink counts
Unique linking domains seen in Common Crawl's link graphs. This is a different dataset than the 0-100 authority scores above: these are raw counts, host-level for mftreatment.com and domain-level for mftreatment.com with all its subdomains combined. Common Crawl covers a large sample of the web, not all of it, so treat counts as comparable between sites rather than absolute totals.